World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
90427
World Ranking
7148
National Ranking
3754

Richard S. Finn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard S. Finn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 622 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard S. Finn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard S. Finn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard S. Finn is affiliated with the University of California, Los Angeles in the United States. Their research primarily focuses on the field of medicine, with extensive work in hepatology and oncology.

Their recent publications include:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020), published in New England Journal of Medicine
  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020), published in Journal of Clinical Oncology

Frequent co-authors collaborating with Richard S. Finn include:

  • Masatoshi Kudo
  • Andrew X. Zhu
  • Ann-Lii Cheng
  • Peter R. Galle
  • Josep M. Llovet

They have contributed to various publication venues, notably:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Hepatology
  • Liver Cancer
  • Cancer Research

Their work spans multiple subfields of medicine including:

  • Hepatology
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Epidemiology

Main research topics covered in their publications feature:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cholangiocarcinoma and Gallbladder Cancer Studies

Best Publications

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

    Jorge A. Marrero;Laura M. Kulik;Claude B. Sirlin;Andrew X. Zhu

  • AASLD guidelines for the treatment of hepatocellular carcinoma

    Julie K. Heimbach;Laura M. Kulik;Richard S. Finn;Claude B. Sirlin

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Hepatocellular carcinoma.

    Josep M Llovet;Robin Kate Kelley;Augusto Villanueva;Amit G Singal

  • Immunotherapies for hepatocellular carcinoma.

    Josep M Llovet;Josep M Llovet;Josep M Llovet;Florian Castet;Mathias Heikenwalder;Mala K Maini

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Molecular therapies and precision medicine for hepatocellular carcinoma

    Josep M. Llovet;Josep M. Llovet;Robert Montal;Daniela Sia;Richard S. Finn

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    Richard S Finn;Judy Dering;Dylan Conklin;Ondrej Kalous

  • Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

    Gottfried E. Konecny;Mark D. Pegram;Natarajan Venkatesan;Richard Finn

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Treating cancer with selective CDK4/6 inhibitors

    Ben O'Leary;Richard S. Finn;Nicholas C. Turner;Nicholas C. Turner

  • CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

    T. Yau;J.W. Park;R.S. Finn;A.-L. Cheng

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Advances in targeted therapies for hepatocellular carcinoma in the genomic era

    Josep M. Llovet;Augusto Villanueva;Anja Lachenmayer;Richard S. Finn

Frequent Co-Authors

Masatoshi Kudo
Masatoshi Kudo Kindai University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Josep M. Llovet
Josep M. Llovet University of Barcelona
Peter R. Galle
Peter R. Galle Johannes Gutenberg University of Mainz
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Ronald W. Busuttil
Ronald W. Busuttil University of California, Los Angeles
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Dennis J. Slamon
Dennis J. Slamon University of California, Los Angeles
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Véronique Diéras
Véronique Diéras Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As the healthcare field grows, many students look for flexible and affordable ways to enter or advance their medical careers. Several online degree and certification pathways exist for those interested in alternative roles within healthcare.

For nurses aiming to take on leadership or specialized roles, exploring cheapest dnp programs online can help you earn a Doctor of Nursing Practice (DNP) in a cost-effective way. Pharmacists or aspiring professionals may consider pharmacy school online options, which provide the flexibility to gain essential credentials while managing work or family responsibilities.

If you are interested in the technical and administrative side of healthcare, online schools for health information management offer programs to prepare you for roles that support patient care with vital data management. Alternatively, completing a medical coding certification online can quickly open doors to entry-level positions in hospitals, clinics, or remote billing offices.

Exploring these online pathways can help you find a fulfilling career in healthcare, no matter your background or location.

Best Scientists Citing Richard S. Finn

Trending Scientists

Recently Published Articles